Tigermed Executive Committee Member, overseeing the Office of the President, Administration, Human Resources, Government Affairs, Translation Business Division, and serving as General Manager of Tigermed Jietong (Medical Device Division). Master of Biochemistry from East China Normal University, licensed pharmacist, and an EMBA. Over 20 years of practical experience in the pharmaceutical industry. Involved in management in biopharmaceutical R&D and production, pharmaceutical product investment management, medical device registration, clinical trials of pharmaceutical and medical devices in Chinese and foreign companies, with a deep understanding of Chinese pharmaceutical product transformation, medical device clinical trial management and registration. 

Dr. Xia Chen holds a Doctor of Medicine in Clinical Medicine from Peking Union Medical College and a Doctor degree in Clinical Pharmacology from Leiden University in the Netherlands. She also holds a Master’s degree in Quantitative Pharmacology from the University of Manchester United Kingdom. Prior to joining Tigermed, she has held critical positions including Associate Professor at Clinical Pharmacology Research Center of Peking Union Medical College, Professor of Clinical Pharmacology at Beijing Tiantan Hospital, and Clinical Reviewer at Center for Drug Evaluation (CDE) of NMPA, with 15 years of clinical R&D experience in hospitals and rich academic research experience.

Shelley Gong joined Tigermed in 2005, focusing on clinical trial quality assurance. She established and maintained the Group's quality management system, ensuring compliance with ICH GCP, China GCP and other relevant regulations, while continuously advancing its internationalization in quality management. In 2015, she was appointed General Manager of Tailan Pharmaceutical, a subsidiary of Tigermed Group, taking full charge of the development and operation of the company's third-party independent audit business. Prior to Tigermed, she worked for nearly a decade in the Medical Department of Roche Pharmaceuticals (Shanghai) Co., Ltd. She served successively as China Regional Lead for international multicenter clinical trials and Head of Quality Assurance & Training. In these roles, she supported Roche's global QA team in establishing localized clinical trial procedures and promoting quality management initiatives in China.

Ms. Chengcheng Yang (Grace), MBA, Zhejiang University. Before joining Tigermed, Ms. Chengcheng Yang worked in PricewaterhouseCoopers, Xizi Otis Company ltd, Xizi Group, Baida Group, Shuanglin Biotechnology Company, Zhejiang United Investment Group Co. ltd. (ZUIG) acting the roles as senior auditor, CFO, Executive Director, Managing Director, etc. She is familiar with China, Hong Kong and International Accounting Standards, specializing in the area of corporate finance, taxation, internal control and operational management with over 20 years’ experience in financial management, investment, financing and capital operation of listed companies. 

Tianrong Ji, M.D, graduated from Peking Union Medical College, Chinese Academy of Medical Sciences in 1994 and has worked at Peking Union Medical College Hospital, Xi’an Janssen, Roche, Baxter, Fresenius-Kabi etc. She joined Tigermed in July 2014, served as the General Manager of TigerYeah Investment, Vice President and Head of Tigermed Investment Bussiness Unit and has more than twenty years of experience in clinical medicine, fund management and corporate M&A.

Ms. Mo Shuang joined Tigermed in April 2013. She has 13 years of legal and compliance work experience, mainly focusing on legal and compliance management in the pharmaceutical field. She has served as the Compliance Legal Director of Tigermed and the Executive Secretary of the Compliance and ESG Committee. She participated in the legal affairs of Tigermed's H-share listing and several investment and M&A transactions. She has in-depth practice and experience accumulation in contract management, investment and M&A legal affairs, compliance system construction, etc.

With a master's degree in pharmacology from Peking Union Medical College, JinLian Li joined Tigermed in 2009 and has over 16 years of experience in clinical research operations and management. In 2019, she was awarded the President's Special Award and began overseeing strategic client management. In October 2024, she took on the role of General Manager of the Domestic Clinical Operations Department for Innovative Drugs, taking full responsibility for clinical operations related to innovative drugs in China. She was also awarded the "Life First" brand ambassador.

She has led and participated in more than 60 domestic and international clinical trials for innovative drugs, covering oncology, hematology, cardiovascular diseases, respiratory conditions, endocrinology, and rheumatology, spanning all phases from I to IV. She has also undergone on-site inspections by the national authorities for over 10 projects, all successfully approved and launched.

With over 20 years of clinical research experience, Jessie is a seasoned industry veteran who has led more than 300 Phase I-IV clinical studies and supported the registration of over 600 drugs and devices globally and regionally. After earning her Master’s and PhD from Iowa State University, Jessie has held diverse roles across all levels of the industry. Since 2019, she has served as the President of Tigermed US, where she has successfully grown the company from a team of one to a thriving organization of industry-leading professionals under her leadership.

Sijia Hu joined Tigermed in February 2006, and transferred to SMO Business Unit in July 2011, where she took charge of large-scale clinical research SMO project management, CRC team system building and operation management. With nearly 20 years of experience in the field of clinical research, she has grown along with the company as one of the first batch of managers, leading her team to achieve remarkable results. She has also actively devoted herself to promoting the development of the industry. She participated in writing and promoting the "Blue Book of China's CRC Industry," led the team to participate in the on-site execution of clinical studies for potential COVID-19 treatment drugs, and was invited as a guest speaker at universities, industry forums, and conferences to share insights on the development of the SMO industry, CRC career information, and organizational management ideas.

EMBA, joined Tigermed in July 2003 and became a member of the Business Development (BD) team in 2006. As the first BD professional at Tigermed, he has been deeply involved in leading the BD team for nearly two decades. Over the years, he has held management positions such as Director of Business Development, Senior Director of Business Development, and Vice President of Business Development. He possesses extensive experience in sales system construction, customer management, and sales team management. As one of the first batch of managers cultivated by Tigermed, Mr. Dai has led the BD team to achieve remarkable results time and again, playing an active role in promoting the steady development of Tigermed within the industry.